Mylan revealed in its recent fourth quarter 2018 earnings call that it had an initial advisory meeting with the FDA regarding a proposed biosimilar onabotulinumtoxinA, referencing the brand-name Botox.
Mylan revealed in its recent fourth quarter 2018 earnings call that it had an initial advisory meeting with the FDA regarding a proposed biosimilar onabotulinumtoxinA, referencing the brand-name Botox.
Mylan said that the FDA’s feedback leads it to believe that the biosimilar approval pathway is viable for this product, and that Mylan could be the first developer to commercialize a biosimilar onabotulinumtoxinA.
The originator onabotulinumtoxinA, a neuromuscular blocking agent, is approved to treat conditions including incontinence due to neurological conditions, prophylaxis of headache in patients with migraine, upper limb spasticity, cervical dystonia, and strabismus, among other indications, such as its cosmetic uses.
Mylan’s development partner for the candidate, Revance, said that successful completion of a biosimilar program could result in FDA approval for all 11 FDA-approved indications for the reference product, and Revance’s president and chief executive officer said in a recent earnings call that “we know what needs to be done, and the FDA has set the right level of expectations” for biosimilar approval.
Allergan and Medytox, makers of the brand-name Botox, face a recent competitor, the recently FDA-approved prabotulinumtoxinA-xvfs, marketed as Jeuveau. Despite being a purified botulinum toxin type A, like the innovator Botox, the newly authorized product was submitted to the FDA under a new Biologics License Application, and was not treated as a biosimilar of the innovator Botox. Its developer, Evolus, in partnership with drug maker Daewoong, sought only indications for the product’s aesthetic use, and the product is not approved for medical indications.
Allergan and Medytox are hoping to block Jeuveau’s sales in the United States; the companies filed a complaint with the US International Trade Commission in which they asked for an investigation into Evolus’ manufacturing of botulinum toxin products. While details of the complaint are confidential, Bloomberg reported that Allergan and Medytox have alleged that the rival product was developed using manufacturing secrets stolen by an Evolus employee.
Allergan and Medytox seek an immediate investigation into whether the product was developed, made, or imported using stolen secrets, and ask for Evolus to be prohibited from selling the drug in the United States.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.